Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...

Premature babies in the UK are to be offered protection against respiratory syncytial virus (RSV) with a single injection of the long acting monoclonal antibody nirsevimab. Every year in the UK around ...

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.